In recent years, improved treatment options, including potent chemotherapeutics, targeted therapies, such as FLT3 inhibitors, IDH inhibitors and Bcl-2 inhibitors, and hematopoietic stem cell transplantation (HSCT) have markedly improved the prognosis of patients with AML; however, AML is still associated with high incidence, mortality and recurrence rates. Here, IDH2 is linked to acute myeloid leukemia.